Binding molecules

What is this patent about?

’522 is related to the field of antibody engineering and the production of therapeutic proteins. Specifically, it addresses the technical challenges associated with manufacturing monoclonal antibodies, which typically require complex assembly of two heavy and two light chains. The background context highlights the high costs of mammalian cell culture and the limitations of traditional antibody fragments, which often suffer from low stability or solubility when produced in simpler bacterial systems.

The underlying idea behind ’522 is the use of transgenic mice to generate high-affinity, heavy chain-only antibodies that bypass the need for light chain association. By engineering a genetic locus that lacks the CH1 domain—the region responsible for binding light chains—the invention forces the production of functional antibodies consisting solely of heavy chains. This allows the animal’s natural immune system to perform VDJ recombination and somatic hypermutation to create diverse, soluble binding domains that do not require complex quaternary assembly.

The claims of ’522 focus on a method for producing a soluble, antigen-specific VH binding domain using a transgenic mouse. The process involves immunizing a mouse that carries a heterologous heavy chain locus containing human V, D, and J segments linked to a constant region lacking a functional CH1 domain. The claims specifically cover the steps of immunizing the animal to trigger affinity maturation, cloning the resulting rearranged VH locus from an antibody-producing cell, and subsequently producing the soluble binding domain.

In practice, the invention works by leveraging the mouse's biological machinery to refine the antibody's fit to a specific target. Because the CH1 domain is absent, the mouse produces antibodies that are secreted as heavy-chain dimers or monomers. Once a high-affinity response is achieved, the genetic sequence for the variable region is isolated. This sequence can then be expressed in various systems, including bacteria or yeast, to produce stable, single-domain binding agents that retain the specificity and potency of a full-sized antibody.

This approach differentiates itself from prior methods by combining the benefits of in vivo selection with the simplicity of single-domain formats. Unlike phage display libraries, which often produce domains with low solubility or weak affinity, this method utilizes the mouse’s natural somatic mutation process to optimize the protein's characteristics. Furthermore, by eliminating the CH1 domain at the genomic level, the invention ensures that the resulting VH domains are intrinsically soluble and functional without the engineering hurdles typically required to stabilize human variable regions.